Long-term Follow-up for Multidrug-resistant Tuberculosis

Patients treated in Peru for multidrug-resistant tuberculosis (MDR-TB) were followed-up for a median of 67 months. Among 86 patients considered cured after completion of treatment, 97% remain healthy; 1 patient relapsed. Employment increased from 34% before treatment to 71%. We observed favorable lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Sonya S., Furin, Jennifer J., Alcántara, Felix, Bayona, Jaime, Sánchez, Epifanio, Mitnick, Carole D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2006
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294679/
https://www.ncbi.nlm.nih.gov/pubmed/16704823
http://dx.doi.org/10.3201/eid1204.041256
_version_ 1782225521823711232
author Shin, Sonya S.
Furin, Jennifer J.
Alcántara, Felix
Bayona, Jaime
Sánchez, Epifanio
Mitnick, Carole D.
author_facet Shin, Sonya S.
Furin, Jennifer J.
Alcántara, Felix
Bayona, Jaime
Sánchez, Epifanio
Mitnick, Carole D.
author_sort Shin, Sonya S.
collection PubMed
description Patients treated in Peru for multidrug-resistant tuberculosis (MDR-TB) were followed-up for a median of 67 months. Among 86 patients considered cured after completion of treatment, 97% remain healthy; 1 patient relapsed. Employment increased from 34% before treatment to 71%. We observed favorable long-term outcomes among MDR-TB patients.
format Online
Article
Text
id pubmed-3294679
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-32946792012-03-06 Long-term Follow-up for Multidrug-resistant Tuberculosis Shin, Sonya S. Furin, Jennifer J. Alcántara, Felix Bayona, Jaime Sánchez, Epifanio Mitnick, Carole D. Emerg Infect Dis Dispatch Patients treated in Peru for multidrug-resistant tuberculosis (MDR-TB) were followed-up for a median of 67 months. Among 86 patients considered cured after completion of treatment, 97% remain healthy; 1 patient relapsed. Employment increased from 34% before treatment to 71%. We observed favorable long-term outcomes among MDR-TB patients. Centers for Disease Control and Prevention 2006-04 /pmc/articles/PMC3294679/ /pubmed/16704823 http://dx.doi.org/10.3201/eid1204.041256 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Shin, Sonya S.
Furin, Jennifer J.
Alcántara, Felix
Bayona, Jaime
Sánchez, Epifanio
Mitnick, Carole D.
Long-term Follow-up for Multidrug-resistant Tuberculosis
title Long-term Follow-up for Multidrug-resistant Tuberculosis
title_full Long-term Follow-up for Multidrug-resistant Tuberculosis
title_fullStr Long-term Follow-up for Multidrug-resistant Tuberculosis
title_full_unstemmed Long-term Follow-up for Multidrug-resistant Tuberculosis
title_short Long-term Follow-up for Multidrug-resistant Tuberculosis
title_sort long-term follow-up for multidrug-resistant tuberculosis
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294679/
https://www.ncbi.nlm.nih.gov/pubmed/16704823
http://dx.doi.org/10.3201/eid1204.041256
work_keys_str_mv AT shinsonyas longtermfollowupformultidrugresistanttuberculosis
AT furinjenniferj longtermfollowupformultidrugresistanttuberculosis
AT alcantarafelix longtermfollowupformultidrugresistanttuberculosis
AT bayonajaime longtermfollowupformultidrugresistanttuberculosis
AT sanchezepifanio longtermfollowupformultidrugresistanttuberculosis
AT mitnickcaroled longtermfollowupformultidrugresistanttuberculosis

Ejemplares similares